drugset / Trial / NCT05462613
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
Timeline
- Start
- 2023-05-09
- Primary completion
- 2029-11
- Completion
- 2030-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 75 mg | Oral |
| Subject | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Regorafenib | Small molecule | 80 mg | — |
| Subject | Regorafenib | Small molecule | 120 mg | — |
| Subject | Regorafenib | Small molecule | 160 mg | — |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |